Verici Dx Is A Healthcare Company Based In Cardiffunited Kingdomfocused On Developing Prognostic And Diagnostic Tests For Kidney Transplant Patientsincorporated In April 2020The Company Operates Primarily In The United States And Aims To Enhance Patient Outcomes Through Personalized Medicineverici Dx Utilizes Ai Assisted Transcriptomic Analysis To Provide Rna Signatures That Help Clinicians Manage Transplant Risks Effectively The Company Offers A Range Of Proprietary Testsincluding Tutiviaa Post Transplant Diagnostic Test For Detecting Acute Cellular Rejectionclaravaa Pre Transplant Prognosis Test Assessing The Risk Of Early Acute Rejectionand Protegaa Developing Liquid Biopsy Aimed At Predicting The Risk Of Fibrosis And Long Term Graft Failurethese Tests Provide Actionable Insights From Patientsbiological Systemssupporting Clinicians In Improving Transplant Success Rates Verici Dx Is Committed To Establishing A Strong Presence In The Diagnostics Market And Is Working Towards Achieving Reimbursement And Inclusion In Clinical Guidelinesthe Company Is Led By Ceo Sara Barrington And Operates With A Specialized Team Of 14 Employees
No conferences found for this company.
| Company Name | Verici Dx Plc |
| Country |
United Kingdom
|
| Address | N/A |
| Telephone | N/A |
| N/A |
